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Abstract 
 
Chalcones are compounds known for their extensive biological properties, which 
include antitumor and anti-inflammatory activities. 
Cervical and prostate cancer are two diseases in which evidence implies 
inflammation as a contributor to tumor development. In the complex tumor micro-
environment, macrophages usually make up a great percentage of the total tumor 
infiltrating cells. 
The aim of this work was to evaluate the cytotoxic effect of a panel of eighteen 
chalcones against cervical and prostate cancer cell lines. Additionally, effect of a 
derivative on nitric oxide (NO) production by macrophages was evaluated. 
The cytotoxic activity of chalcone derivatives was evaluated by the MTT-viability 
assay after 48 h exposure to the compounds, against HeLa, androgen dependent LNCaP 
and androgen independent PC-3 cancer cell lines. Inhibition of NO was evaluated in 
RAW 264.7 murine macrophages, by Griess reaction. 
All chalcone derivatives displayed cellular toxicity against the three cell lines. 
Among studied compounds, MB4 demonstrated one of the highest cellular inhibition in 
the screening, showing 76.93 ± 4.56 % and 87.6 ± 3.69 % of cytotoxicity for LNCaP and 
PC3 cell lines respectively, while inhibiting 78.28 ± 3.03 % on HeLa, at the highest 
concentration tested (20 µM). It resulted in one of the highest cellular inhibition values 
for the referred concentration, but achieved great activities for inferior concentrations, for 
every cell line. 
Most of the compounds seem to inhibit PC-3 and LNCaP cell lines without 
significantly differences of sensitivity between them. However, few showed increased 
cytotoxicity against PC-3 and less sensitivity was observed for LNCaP (p < 0.05). Overall, 
compounds revealed an inferior inhibition of HeLa, when compared to prostate cancer 
cell lines. 
Preliminary results of MB4 effect on the production of NO suggest strong 
inhibition, not related with cell death.  
 Results demonstrate that these chalcone derivatives are potent antitumor 
compounds against cervical and prostate cancer cell lines, and additionally, derivative 
MB4 demonstrating strong anti-inflammatory activity in macrophages. 
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Resumo 
 
Chalconas são compostos que possuem inúmeras propriedades biológicas, 
como por exemplo, os seus efeitos anti tumorais e anti-inflamatórios. 
O cancro do colo do útero e o da próstata são duas doenças nas quais existe 
evidência de que a inflamação pode contribuir para o desenvolvimento do tumor. No 
complexo microambiente tumoral, os macrófagos representam uma grande parte do 
número de células infiltrativas. 
O objetivo deste trabalho passou pela avaliação do efeito citotóxico de um painel 
dezoito chalconas sobre linhas celulares de cancro do colo do útero e da próstata. 
A atividade citotóxica foi avaliada pelo ensaio de viabilidade de MTT após 48 
horas de exposição aos compostos, em linhas celulares de HeLa, androgénio-
dependente LNCaP, e androgénio-independente PC-3. Adicionalmente, foi estudada a 
inibição da produção de óxido nítrico (NO) em macrófagos RAW 264.7, pelo ensaio de 
Griess. 
Todos os derivados demonstraram toxicidade celular contra as três linhas 
celulares testadas. Dos compostos estudados, o derivativo MB4 demonstrou elevada 
citotoxicidade, inibindo 76.93 ± 4.56 % e 87.60 ± 3.69 % em LNCaP e PC3 
respetivamente e 78.28 ± 3.03 % na linha celular HeLa, para a concentração mais 
elevada (20 µM). Este derivado não só resultou numa das inibições mais elevadas para 
a referida concentração, como demonstrou uma atividade alta para concentrações 
inferiores, em todas as linhas celulares.  
A maioria dos compostos parece inibir as linhas celulares PC-3 e LNCaP sem 
diferenças significativas entre elas. No entanto, alguns derivados demonstraram 
cytotoxicidade superior contra PC-3 e sensibilidade inferior para LNCaP (p < 0.05). 
Globalmente, os compostos revelaram uma inibição inferior em HeLa, quando 
comparado com as linhas de cancro da próstata. 
Resultados preliminares do efeito do derivado MB4 na produção de NO 
demonstram forte inibição, que não estará relacionada com morte celular. 
 Os resultados demonstram que estes derivados de chalconas possuem uma 
potente atividade anti tumoral sobre as linhas celulares de cancro do colo do útero e da 
próstata e, adicionalmente, o derivado MB4 possui uma forte atividade anti-inflamatória 
em macrófagos. 
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Cancer – generic overview 
  
 Cancer has become a public health problem, with its global burden expected 
to increase in the following decades [1].  
 The disease is the consequence of a clonal expansion of a single abnormal cell 
that leads to uncontrolled growth [2]. It is multifactorial with many risk factors known, 
such as smoking, obesity and sedentarism, but is also a natural consequence of ageing 
and higher life expectancy [3]. 
 Cancer is a disorder in which genetic and epigenetic alterations are 
accumulated in a complex process known as carcinogenesis [4]. These occur mainly as 
mutation in genes resulting in the activation of oncogenes and/or inactivation of tumor-
suppressor genes [5]. Ultimately leading to deregulation of signaling pathways and 
acquisition of a neoplastic phenotype [5, 6]. The acquisition of a malignant phenotype is 
characterized by acquisition of growth autonomy, reducing the dependence on tumor 
microenvironment stimulus; insensitivity to anti-proliferative signals and apoptosis; 
replicative immortality; angiogenesis capacity; and tissue invasion and metastasis 
formation [7, 8]. 
 
Cervical Cancer 
 
 Cervical cancer is still one of the most diagnosed types of cancer among women. 
Globally, it is the third most diagnosed and the forth cause of death by cancer [1]. 
Squamous cell carcinoma is the most common type of cervical cancer, 
accounting 70 % to 80 % of the cases, followed by 20 to 25 % of adenocarcinomas [9].  
Human Papilloma Virus (HPV) persistent infection is highly associated with 
cervical malignancies. It is, in fact, the most significant cause of this type of cancer, 
accounting over 99 % of all cases [10, 11].  
 The introduction and practice of vaccination against several types of HPV has led 
to a significant decrease in cancer incidence in developed countries. However, the 
scenario does not correlate in developing countries, but mostly due to the lack of 
screening and detection of the precancerous lesion [1, 12]. 
HPV genomic constitution comprises distinct regions and functions. Early genes, 
encode proteins useful for genomic transcription and regulation; late genes are useful 
for the construction of capsids [13]. Two main early genes, E6 and E7 are classified as 
oncogenes and are commonly expressed in cervical neoplasia [11, 13]. 
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This virus is capable of infecting both cutaneous and mucosal epithelium, though 
most of genital neoplasia are consequence of the mucosotropic type [14]. Even so, they 
are classified has low-risk and high-risk, according to the risk of developing genital 
tumors [10].  
The infection is often carried out in the basal layer of the cervical epithelium and 
a minority of the women infected develop a more serious lesion that progresses to high 
grade squamous intraepithelial lesion [15].  
While an infected cell usually dies, another portion integrates E6 and E7 genes 
into the cell DNA [16, 17]. These genes encode proteins known for promoting cell 
proliferation and inhibiting apoptosis [6, 13, 18].  
 In high risk HPV, E6 complexes with great affinity to the tumor suppressing 
protein p53 and promotes its degradation. Similarly, E7 binds to retinoblastoma protein 
(pRb), also a tumor suppressing protein, preventing its functions [6, 10], reason why 
these HPV types are highly associated with cervical carcinogenesis. 
 
Prostate Cancer 
 
Prostate cancer is the second most diagnosed cancer among men worldwide, 
being one of the deadliest in developed countries [1]. 
Even though mortality and incidence rates have been decreasing, mostly due to 
screening and early detection, it is still one of the most prevalent cancers in men [19]. 
Prostate cancer is a heterogeneous and frequently multifocal, with acinar 
adenocarcinoma being  the most observed histological pattern [20]. 
Most prostate carcinomas are indolent, however, a third of the cases reveals itself 
as locally invasive and capable of establishing metastasis. The bone is the preferential 
tissue site for metastasis, followed by the lungs and liver [21]. 
It is not fully understood how prostate cancer is originated, but three main lesions 
have been accepted as precancerous lesions and precursors of this type of cancer 
(Figure 1): 
Proliferative inflammatory atrophy (PIA) arises in the peripheral zone of the 
prostate and is characterized by glandular atrophy and increased cellular proliferation 
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[22]. With the accumulation of malignant changes, PIA can undergo transition and 
develop to prostatic intraepithelial neoplasia (PIN), or directly originate prostate cancer.  
PIN is characterized by a thicker epithelial layer and indistinctly basal and 
secretory layers [21]. Usually, PIN expresses characteristics of early invasive carcinoma. 
It can be divided into low or high grade, the first having a low risk of progressing to 
prostate cancer [20]. 
The third precursor lesion is atypical small acinar proliferation (ASAP). It occurs 
when atypical epithelial cells form localized small acinar structures [23].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
High grade PIN and ASAP are commonly found in prostate biopsies [23]. 
In addition, somatic gene encoding π-class glutathione S-transferase protein  
(GSTP1) silencing is an epigenetic alteration that has been found in the majority of cases 
of prostate cancer [24-26]. GSTP1 is an important oxidative and carcinogen detoxifying 
enzyme [26]. Therefore, its epigenetic silencing has also been proposed to trigger 
prostate carcinogenesis [27]. 
Figure 1 - Prostate cancer precursor lesions and development into cancer. 
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 Prostate cancer might be a consequence of both environmental and 
genetic/hereditary influence [28], however, recently, inflammation has been proposed 
and linked to the disease. Infection, exposure to carcinogenic compounds, and chronic 
inflammation might take part in the aetiology of prostate cancer [29] as there is evidence 
of inflammatory infiltrates that precede prostate lesions [28]. 
 
Immune System 
 
The immune system is a complex network of different cells and molecules with 
specific roles against microorganisms, tumor cells and toxins, and is crucial for 
homeostasis maintenance. It comprises two major responses: innate and adaptive 
immunity [30]. 
Innate immunity is usually the first line of defense in which phagocytic and antigen 
presenting cells, like macrophages, natural killer cells (NK), neutrophils and dendritic 
cells, and circulating mediator molecules, such as the complement and cytokines, trigger 
an immediate response [30, 31].  
Adaptive immunity is antigen-specific and includes not only cellular components, 
such as B and T lymphocytes, but also mediators like cytokines and antibodies [32].  B 
lymphocytes are responsible for the production of antibodies, alongside with the help of 
T lymphocytes. The latter, can also trigger immune phagocytic cells to kill intracellular 
pathogens or suppress viral infected cells [30]. 
Innate and adaptive responses work together to defend against pathogen 
invasion infection and to protect against transforming cells [30, 32]. 
The immune system also takes part in the tumor microenvironment, as a means 
of inflammation, through the presence of immune cells, cytokines and chemokines 
interactions with both stromal cancer cells, that has an effect on the tumor outcome [31]. 
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The NF-ĸB Pathway 
 
The nuclear factor kappa-light-chain-enhancer of activated B cells (NF-ĸB) has 
been discovered and described as a nuclear transcription factor [33]. The factors of the 
NF-ĸB family are known to play a role in inflammation, innate immune response, viral 
replication, and to affect the development and survival of cancer [6, 34, 35]. 
The mammalian NF-ĸB subunit is composed of five proteins, all part of the avian 
reticuloendotheliosis viral oncogene homolog (REL): p65, c-Rel, RELB, NF-ĸB1 and NF-
ĸB2 (also known as p50 and p52, respectively) [34, 35]. The last two, NF-ĸB1 and NF-
ĸB2, are firstly synthesized as precursor proteins that later undergo a proteasomal 
processing [36]. The members of the factor complex NF-ĸB form homo- or heterodimers 
and when activated, bind to the DNA inducing the transcription of diverse target genes 
[6, 34, 35]. 
The signaling pathway can be quickly activated as a defense response to 
infection and stress [34], but also as a consequence of other environment stimuli such 
as microbial products and pro-inflammatory cytokines [37]. There are two main routes of 
activation: the canonical and non-canonical (or alternative routes) [6]. The first is 
associated with tumor promoting action and anti-apoptotic properties, while the second 
can have tumor suppressing capacity and promote apoptosis [35], evidencing 
contrasting roles for this pathway depending on the cellular context [34]. 
 
Macrophages 
 
Macrophages are phagocytic cells of the immune system that have a crucial role 
in the organism defense as well as homeostasis regulation [38].  
They act as phagocytic cells taking part in the clearance of neoplastic and 
apoptotic cells [39]. 
They interact with both innate and adaptive immune response taking part in 
inflammation processes  [38], secreting inflammatory cytokines [39]. 
Macrophages differentiate from monocytes originated in the bone marrow, being 
able to react to many environment stimulus, adopting different phenotypes and functions 
[40]. These cells can alternate between polarization states, commonly known as 
inflammatory states, mirroring the lymphocyte T helper dichotomy (Th-1/Th-2) [41]. 
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Frequently, they are referred to as M1, having a pro-inflammatory activity or, M2, which, 
in contrary, has anti-inflammatory properties [42], following a binary classification. 
However, in spite of the great diversity of macrophage lineages (Figure 2), and because 
it does not represent the complexity of in vivo profiles/phenotypes, macrophages can be 
further classified in subsets [43]. 
 
 
Figure 2 - Macrophage polarization, functions and cytokines profiles. Microenvironment stimuli drives 
macrophages towards classic activation (M1 phenotype) and alternative activation (M2 phenotype). 
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Classically activated, or M1 state, is triggered as a response to cytokines such 
as interferon-γ (IFN-γ) and gram-negative bacteria lipopolysaccharide (LPS) through toll-
like receptors (TLR) activation. This subset is characterized by the tumor cytotoxicity 
capacity, the production of reactive oxygen species [44] and pro-inflammatory cytokines 
such as tumor necrosis factor α (TNF-α), Interleukin (IL) 1, IL-6, IL-12, IL-23, and also 
antigen presenting capacity [45]. Nitric oxide (NO), is also a molecule produced by 
macrophages that has cytotoxic activity and interplays a role in many immune cells [46, 
47]. 
On the other hand, alternatively activated, or M2 state is usually a consequence 
of IL-4 and IL-13 stimulation [45]. This type is linked to tumor progression, angiogenesis 
and tissue remodeling and repair. It is usually correlated with a poor outcome in many 
cancers [48], however, this classification should be further divided in subsequent 
subtypes.  
IL-4 and IL-13 polarize macrophages into a M2a subtype, related with allergic 
reactions, the killing of intracellular pathogens and matrix remodeling. M2a subtype is 
characterized by the production of polyamines, matrix metalloproteinases (MMPs), IL-
10, IL-1RI and IL-1RII cytokines. 
Immune complexes induce polarization towards an M2b type, which is in charge 
of the inflammation suppression and immunoregulation. 
Finally, IL-10 drives macrophages to an M2c subtype, the most 
immunosuppressive type. It stimulates regulatory T cells and exerts matrix remodeling. 
M2c not only secretes IL-10 and MMPs, but also tumor growth factor β (TGF-β) [49-51]. 
While some studies state that macrophages in normal tissues exert cytotoxic 
activity, tumor-associated macrophages (TAM) could promote the growth and 
progression of tumors [52].  
 Tumor microenvironment has a crucial role in the development of cancer. This is 
a complex environment composed of infiltrating cells, blood vessels, secreted factors, 
which in sum, comprises cellular and non-cellular components [53]. Furthermore, 
macrophages can also be interpreted as biomarkers in cancer and predictors of disease 
outcome and treatment efficacy [54]. 
 Due to the microenvironment influence on macrophages polarization and this cell 
characteristic plasticity, macrophages are often implied in cancer. But its role is not 
always clear and differs within different types of cancer [53]. Nonetheless, these two 
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features make macrophage subsets a possible and interesting therapeutic target in 
cancer [55]. 
 
TAMs and cervical cancer 
 
The presence of TAMs in cervical cancer has been correlated with a poor 
prognosis [56]. 
Evidence exists that tumor progression is accompanied with TAMs increasing 
density within tumor nest, reflecting a role in tumor progression (Table 1).  
Recent researches suggest that the interaction between TAM and tumor cells, 
synergistically promote angiogenesis [48, 57, 58] and lymphangiogenesis [59], which 
might also be encouraging cancer invasion [48].  
 Moreover, Petrillo et al. work showed that the differentiation of M2 macrophages 
may lead to a resistance to platinum therapies, which is in accordance with similar 
reports for several cancer types showing evidence of a reduced effect of chemotherapy 
and radiotherapy [60, 61]. Corroborating, chemotherapy agents induced the proliferation 
of M2-like macrophages which might lead to an indirect therapy resistance [62]. 
In fact, cervical cancer supernatants can induce the polarization of macrophages 
from M1 (through LPS activation) into a M2 phenotype, reducing the content of pro-
inflammatory cytokines [63], leading to tumor promoting consequences, as reported in 
Pedraza-Brindis et al. work [64]. 
Furthermore, another work identified a relationship between M2 TAMs and 
invasion patterns in squamous cervical cancer, noticing a significant increase in M2 
macrophages content in tumor tissue arrays with diffuse infiltration patterns [65]. 
Taken altogether, the tumor microenvironment, in cervical cancer, might be 
responsible for the polarization of macrophages into a M2 phenotype, characterized by 
a low antitumor activity, which facilitates the tumor development. Reason why TAMs 
density in cervical tumors is associated with a poor disease outcome and poor response 
to treatment [49, 61]. 
  
 
10 
 
TAMs and prostate cancer 
 
In prostate cancer, the content and purpose of TAMs can be controversial. 
A higher density of TAMs was observed in prostate cancer, in comparison to the 
benign tissue [66], suggesting that macrophages might affect the disease course. 
Research also suggested that a high density of TAM cells is associated with a poor 
survival time [67], and that macrophage accumulation resulted in a protective effect 
against radiotherapy, in mouse tumor models [68]. Additionally, TAMs may also play a 
part in the promotion of prostate cancer metastasis [69].  
Furthermore, Fujii et al. concluded that the infiltration and involvement of M2 
polarized macrophages is an important cause of prostate carcinogenesis [70]. 
Thus, the TAMs M1/M2 ratio might reveal itself crucial in prostate cancer 
prognostic and disease outcome and a higher proportion of M2 tumor-associated 
macrophages is, in fact, predictor of prognosis [70].  
So, in summary, the presence of TAMs in prostate cancer is usually a negative 
predictor of the outcome [66-70]. 
Contrarily, another author noted that a higher density was inversely related with 
the disease progression and the presence of lymph nodes. Additionally, the reduced 
infiltration of TAMs was an independent predictor for time to disease progression [71]. 
Yet, recently, a meta-analysis determined that the progression of prostate cancer 
is followed by an increase in TAMs, suggesting its tumor promoting properties [72]. 
Nonetheless, the controversial significance of TAMs in prostate cancer might also 
be a consequence of the use and attempt to classify macrophages inflammatory states 
based on their activation and cytokine produced. The in vivo scenario comprises a much 
more complex network of components acting within the tumor microenvironment, 
completely distinct to in vitro assays [43].  
Furthermore, the M1/M2 macrophage ratio and their location within the tumor 
might also be an explanation to the conflicting results [49]. 
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Cytokines 
 
Cytokines are secreted proteins capable of modulating the immune response 
[73]. They can be produced by different cell types in consequence to stimulus, following 
mechanisms of paracrine and autocrine activity, interfering with the interaction and 
communication between cells. Cytokines present pleiotropy, meaning that the same 
cytokine can be produced by several types of cells and that the same type of cytokine 
can affect myriads of cell types [74]. 
Based on their influence, these molecules are known as pro-inflammatory and 
anti-inflammatory agents, defining the lymphocytes lineages (Th-1/Th-2) [41]. 
TNF-α is an inflammation promoting cytokine mainly produced by activated 
macrophages, but also by other immune cell types, such as monocytes, T cells or NK 
[75]. It is a potent mediator of the inflammatory response that can, among other functions, 
induce the production of other cytokines and stimulate the expression of adhesion 
molecules [74]. It can also promote the growth of normal cells and, in contrast, exert 
cytolytic activity against tumor cells. Its myriad of functions are a result of its pleiotropy 
[75]. In addition, some allelic variations of cytokines produced by macrophages, such as 
TNF-α might even endorse the risk of cervical cancer progression [76]. 
TGF-β is an anti-inflammatory cytokine. Its purposes are related with regulation 
of the immune response and the preservation and maintenance of self-tolerance [77]. 
TGF-β inhibits the synthesis of several cytokines, including TNF-α. In addiction it also 
constrains the production of nitric oxide (NO) by macrophages [74]. Aberrant expression 
and activity is associated with cancer progression alongside with tumor mutations [77]. 
IL-1 is a cytokine mainly produced by monocytes and macrophages. There are 
two types of IL-1: IL-1α and IL-1β.  While IL1-α is thought to modulate the intracellular 
environment, IL1-β has pro-inflammatory activity and is commonly expressed in 
response to microbial compounds [75]. Associated with tumor progression, angiogenesis 
and metastasis, this molecule is  present in tumors whose prognosis are worse [78]. 
IL-6 is another inflammatory cytokine that can be produced by several cells, 
including prostate cancer and stroma cells [79]. This cytokine can also be induced by 
TNF-α and IL-1 [74]. It plays different biological activities, but the one for its most critical 
roles is intervening  in the synthesis of acute phase proteins in acute inflammation and 
regulating T-cell differentiation [80]. Reports state that this molecule protects cancer cells 
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against DNA damage and apoptosis [81]. Though, there is divergent evidence regarding 
IL-6 effects in tumorigenesis [82].  
IL-10 is produced by many immune cells and is known for repressing pro-
inflammatory cytokines and stimulating the production of anti-inflammatory cytokines 
[74]. IL-10 has a dual action. While it is capable of inhibiting an inflammatory response, 
IL-10 can also promote de expansion of cytotoxic lymphocytes, known for their anti-tumor 
activity [83]. In cancer, IL-10 exerts different effects depending on the cytokines content 
and surrounding conditions, with reports defending tumor promotion in the beginning of 
the process of tumorigenesis, and others highlighting tumor inhibition in established 
cancer [84]. 
 
Chalcones: chemistry and biological activities 
 
The chemical structure of a chalcone, 1,3-diaryl-2-propen-1-one, consists of two 
aromatic rings joined together by a three-carbon α,β-unsaturated carbonyl system 
(Figure 1) [85]. 
Chalcones are organic chemical compounds that occur naturally in plants [86] 
and are traditionally used for their therapeutically effect and benefits [85]. 
These compounds were highlighted for their pharmacological potential and the 
possibility of originating myriads of derivates with specific and promising biological 
activities [87]. 
They can exist in many forms in nature [88] and be easily synthetized [86, 88]. 
Chalcones are precursors of flavonoids [89], polyphenols that protect plants against 
reactive oxygen species, ultra-violet radiation and pathogens [90]. 
 
 
 
 
 
 
 
Figure 3 - Generic chemical structure of a chalcone. 
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They have been extensively studied and exploited regarding their wide range of 
biological properties [91], including antioxidant, anti-microbial, anti-allergic [92], anti-
diabetic [93], anti-inflammatory [94] and anti-tumor [95]. 
Currently, two chalcones have been approved and used in clinical practice: 
Sofalcone in the treatment of gastrointestinal ulcers and protection against Helicbacter 
pylori [96] and Metochalcone, a choloretic agent [97].  
In cancer research, efforts have been made to clarify and characterize the 
mechanisms of action of chalcones  [98]. There is convincing evidence that these 
compounds can exert anti-tumor and chemosensitizer effects by acting as inhibitors of 
multidrug resistance channels, which are membrane proteins that transport substances 
including drugs or toxins and are associated with drug resistance [88]; Inhibitors of 
hormone components and synthesis that otherwise can promote tumors growth and 
proliferation [88, 99]; inhibition of protein deacetylation by histone deacetylases that are 
found deregulated in many cancers [85]; stabilization of the tumor suppressor protein 53 
(p53) , responsible of inducing cellular arrest [100, 101]; inhibition of angiogenesis [102] 
through the suppression of NF‐κB activation in pancreatic cancer [103] and further on. 
It has been demonstrated that chalcones can inhibit the cellular cycle, leading to 
cell cycle arrest and induction of apoptosis, by means of interactions with cyclins and 
cyclin-dependent kinases [95, 104]. In fact, these compounds can take action on the cell 
cycle arrest of human cancer cell lines in either G1 [105] or G2/M phases [106]. 
Additionally, it is reported that chalcones derivates can release protein p53 from 
complexes that prevent its transcriptional activity and obstruct its regulatory function on 
the cell cycle [104, 107]. It is the case of the murine double minute 2 (MDM2) that 
negatively regulates p53, inhibiting it. Synthesized chalcones can disrupt the interaction 
between the two proteins, releasing p53 and restoring it function [108]. 
One of the apoptosis mechanisms comprises TNF proteins, namely tumor 
necrosis factor–related apoptosis-inducing ligand (TRAIL), that interacts with death 
receptors in cancer cells [95, 109]. Chalcone derivates induce cellular death [110], 
targeting the TRAIL pathway [104, 109] and even inducing an increased expression of 
TRAIL components resulting in the apoptosis of tumoral cells with TRAIL-resistance 
[111]. 
Chalcones can also regulate the NF-ĸB pathway by interacting with multiple 
possible components leading to the pathway inhibition, due to its molecular structure 
[104]. 
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Chalcones and cancer 
 
 Chalcones have been highlighted for their potential antitumor effect [88] and 
structural modification has been a strategy to improve their distribution, absorption, 
function and effect [98]. Recently, hybrid chalcones, reportedly to have an increased 
anticancer activity [95, 112] and a reduced toxicology reaction, were shown to have 
indeed effect against cervical cancer cell lines [113].  
 Singh et al. work used a hybrid molecule that inhibited the proliferation of cervical 
cancer cell lines HeLa and C33A, with reported cell cycle arrest and p53 upregulation 
[112]. 
Similarly, another work investigated the effect of chalcone based compounds 
upon HeLa cells and noticed that these cells were more sensitive to chalcones, having 
a comparable cytotoxicity to cisplatin’s chemotherapy alkylating agent. Chalcones also 
arrested the cell cycle at S and G2/M phases, inducing apoptosis [113].  
Xanthohumol, another natural chalcone [98], effect on Ca Ski cervical cancer line, 
was tested and researchers also reported inhibition of proliferation, cell cycle arrest at S 
phase, and p53 increased expression, as well as other proteins involved in programmed 
cell death [114], corroborating chalcones cytotoxicity, mechanisms of action through 
DNA damage [115], cell cycle arrest and pro-apoptotic proteins upregulation. [98, 112, 
113]. 
  Chalcones potential has been investigated and tested in countless cancer cell 
lines, including prostate cancer cells [85]. 
Researchers showed that a natural chalcone, named Flavokawain B, could inhibit 
the growth of prostate cancer cell lines. However, it was more effective upon androgen-
receptor (AR) negative, hormone refractory cancer cells. As previously noted, apoptosis 
occurred with an increasing expression of pro-apoptotic proteins [116]. 
Xanthohumol effect was also tested in prostate cancer cells, leading to growth 
inhibition of hormone-sensitive prostate cancer cells, and orientation of apoptosis, in 
which signaling pathways might have been involved [117]. 
Another work involving Xanthohumol allied to an endogenous ligand involved in 
immune surveillance, studied the anti-tumor activity upon androgen-sensitive prostate 
cancer cell line LNCaP, demonstrated enhanced cytotoxicity and apoptotic outcome 
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[118]. An additional chalcone tested on prostate cancer cells caused cell cycle arrest, 
which resulted in reduced cell proliferation and apoptosis [119]. 
All these studies provide a solid evidence that chalcones have potential and exert 
anti-cancer activity against multiple cancer cell lines, and that they might be a strategy 
not only for chemoprevention but also for treatment [88, 116, 117]. 
 
Chalcones and the immune system 
  
Chalcones have demonstrated their potential to modulate the immune system 
[120], interacting and having different effects on the several types of immune cells [121]. 
In fact, a study reported a decrease of Il-6 and TNF-α secretion in LPS induced 
mouse dendritic cells, which cytokines closely linked to inflammation promotion [122].  
In basophils, chalcones diminished degranulation and histamine production, 
showing a role in modulating the allergic response [123, 124]. As for neutrophils, 
chalcones have been related with reduced respiratory/oxidative burst, inhibition of 
superoxide anion and NO production [121, 125].  
In monocytes/macrophages, as reported in several studies, compounds resulted 
in inhibition of NO production, by suppressing iNOS (inducible nitric oxide synthase) 
expression, which is thought to happen through interactions with  the NF-ĸB pathway 
and NF-ĸB inhibition [121, 126]. As well, TNF-α levels were also significantly reduced 
[126]. 
Furthermore, studies found that testing chalcones had the ability to reduce the 
expression of many cytokines in T lymphocytes, namely IL-2, IL-4, IL-5, IL- 13, TNF-α 
and IFN-γ [92, 127, 128] and even inhibition of cytotoxic T cell proliferation [127, 128]. 
Taken altogether, chalcones can interact with immune cells, taking part in 
inflammatory pathways and cytokines production, and act as modulators [129, 130], 
regulating the immune response [130]. 
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Abstract: 
Inflammation is essential in cancer promotion. The presence of tumor-associated 
macrophages (TAMs), implied in tumor microenvironment, is usually associated with 
tumor progression and worse prognosis in several cancers, including cervical cancer. 
The present review summarizes the findings of the several studies published concerning 
TAMs role in cervical cancer and clinical findings, as well as, the influence on cervical 
cancer cell lines. The majority of the studies concluded that TAMs increase density is 
proportional to the increasing severity of a malignant cervical lesion, in association to 
this. TAMs are usually polarized into a M2 phenotype that promotes and benefits tumor 
progression, which is in agreement with a worse outcome of the disease. 
 
Keywords:  
Cervical cancer; cervical intraepithelial neoplasia; tumor-associated macrophages; M1; 
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Introduction 
Cervical cancer is one of the most frequently diagnosed malignancy among 
women worldwide 1, being Human Papilloma Virus (HPV) persistent infection the most 
significant cause of this type of cancer 1,2. When the immune system cannot prevent the 
persistent HPV infection, HPV can transform normal into malignant cells which, 
promoting chronic inflammation and, with this, advance precursor lesions 3. 
Evidence has suggested that Inflammation is an essential key in the process of 
initiation and promotion of cancer  4, being reported that it is responsible for tumor 
17 
 
development, invasion 5 and angiogenesis 6. In fact, solid tumors are infiltrated by 
immune cells suggesting that a significant percentage of cancer cases are caused either 
by chronic infection or inflammation 7,8. 
Macrophages are immune cells that carry phagocytosis and immune surveillance 
9. While they are also known to have antitumor activity, they are frequently implied in the 
tumor microenvironment, being referred to as tumor-associated macrophages (TAMs) 
10. Plasticity is a characteristic of TAMs, which are influenced and polarized in response 
to an environmental stimulus 11. Its role in cancer is not yet fully established 12, but 
convincing evidence demonstrates that TAMs can promote and sustain cancer 
malignancy 13. 
Most of studies resembling the presence of TAMs report an association with 
cancer progression and a worse disease outcome 11,14. The same seems to occur in 
cervical cancer 15, however the association is not always reproducible for every tumor 
stage or lesion 16 and ranges diverse deductions based on the macrophages phenotypes 
17. Thus, the main goal of this review is to summarize the observations of the several 
studies published concerning TAMs role in cervical cancer, either by their tumor 
promoting properties or implications in the disease prognosis. 
 
Material and methods 
A search was performed in PubMed, Elsevier, Science Direct and GoogleScholar 
for all studies including terms related to cervical cancer (e.g. cervical cancer, cervix, etc.) 
and terms related to tumor-associated macrophages (e.g. tumor-associated 
macrophages, TAMs, M1, M2, etc.). Initially, 24 studies were selected and analyzed. 
From these and for this review, scientific reports that included macrophages and their 
relationship with cervical cancer and in vitro experiments with macrophages and cervical 
cancer cell lines were selected. 
 
Tumor Associated Macrophages  
Macrophages differentiate from bone marrow monocytes and can adopt different 
phenotypes and express specific markers 18,19.  
As said before, macrophages can be driven into different polarization states, 
known as inflammatory states, expressing different cytokines profiles 20. Classically 
activated M1 macrophages have antitumor activity in established tumors 21. Nonetheless, 
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M1 phenotype disfunction in chronic inflammation situation can result in cancer 
promotion, due to oxidation products released 22. Alternatively activated M2 
macrophages have tissue repair and remodeling properties, enhance angiogenesis 23, 
invasion 24 and promote tumor development 25. 
 In humans, cluster of differentiation 68 (CD68) is a generic macrophage marker, 
and CD163 is a member of the scavenger receptor cysteine-rich (SRCR) that is 
predominantly expressed in alternatively activated TAMs (M2 phenotype) and 
associated with tumor promoting activity 17,25. 
Macrophages are usually known for their cytotoxic and antitumor activity; 
however, they can also have an important role in tumor promotion by secreting factors 
that will enhance tumor invasion and stimulate tumor metastasis 26. Macrophages are 
characterized by their plasticity, meaning that tumor microenvironment, with its complex 
network composed of infiltrating cells, blood vessels and secreted factors influence its 
polarization towards phenotypes that expresses a different cytokine profile 12. With this, 
TAMs can be recruited and influenced by tumors and end up on aiding and promoting 
tumor proliferation 27. 
TAMs contribute towards inflammation and tumorigenesis, taking part in the 
hallmarks of cancer (Figure 1). TAMs facilitate immunosuppression by direct interaction 
with T cells or release of immunosuppressive cytokines and proteases, with the tumor 
avoiding immune destruction. Invasion and metastasis are activated by secretion of 
metalloproteinases, proteases and cathepsins that take part on cell adhesion. 
Angiogenesis is induced by the release of angiogenic factors, such as vascular 
endothelial growth factor (VEGF) 27-29.  
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The presence of TAMs has been associated with a poor disease outcome, a 
poor prognosis and a shorter survival in several and different types of cancer 15,30,31. In 
fact, a high density of TAMs have been related to a bad prognosis in 80 % of published 
studies 32. 
Cytokines produced by macrophages in the tumor microenvironment, such as 
TNF-α, can be associated with a higher risk for developing invasive cervical cancer 33. 
Even though studies normally focus on the effect of macrophages and tumor 
progression, others demonstrate that certain cytokines polymorphisms are related 
themselves with increased risk of developing cancer 33,34.  In addition, polymorphisms in 
endothelial cell-specific form of nitric oxide synthases (macrophage associated enzymes 
that secretes cytotoxic mediators) have been strongly associated with advanced prostate 
cancer, as well as, the development of prostate bone metastasis 34. However, TAMs 
density was also linked to a better prognosis in different types of cancer 35,36. For 
instance, the presence of TAMs in colorectal cancer might enhance survival in patients 
32. 
 
 
Adapted from Aras, S. et al. and Hanahan, D. et al. 
Figure 4 - The major role of tumor associated macrophages (TAMs) in the hallmarks of cancer. 
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TAMs and cervical cancer: clinical findings 
Table 1 lists evidence, to date, for the presence of TAMs and its influence in 
cervical cancer tumors, using cervical tissue specimens, using International Federation 
of Gynecology and Obstetrics (FIGO) staging system for endometrial and cervical 
cancers 37 or cervical cancer precursor lesions classification, termed cervical 
intraepithelial neoplasia (CIN I to III) 38  
Whereas the presence of macrophages infiltration has been associated with more 
advanced stages and a worse outcome, some studies found contrary associations 39. 
Overall, when compared to normal tissues, the macrophage density was higher 
in situations of either precursor lesions or in established cervical cancer, with invasive 
cervical cancer being the reported situation with a higher density in TAMs (Table 1). This 
goes in agreement with reports stating that TAMs number/density is linked to a poor 
prognosis in cervical cancer 31 and other types of cancer, such as breast, gastric, head 
and neck, among others 40-42. 
But the exception occurs and there are studies, where macrophage counts 
neither correlate with tumor stage, nor with survival 39. While studying the clinical and 
functional significance of TAMs, Ding et al.  noted an enrichment of macrophages in 
cancer nests compared to less developed lesions and normal tissue but found no 
significant correlation with FIGO stage 16. 
 The content of M2 TAMs was found to be elevated in neoplastic tissue 43 and 
there was a close interaction between the severity of the lesion and an increase in M2 
macrophages density 44. Furthermore, CD163+ macrophages, demonstrated a stronger 
correlation with the advanced FIGO stage and lymphatic metastasis than CD68+ cells 17.  
As noted, a higher density of TAMs was found in carcinoma in situ and 
established cervical cancer in Jiang et al. and Utrera-Barillas et al. works, respectively. 
These authors also related the interaction between TAMs and tumor cells to 
synergistically promote angiogenesis 45,46. Ding et al. also highlighted the possibility of 
macrophages in tumor stroma being actively involved in lymphatic metastasis. Taken 
altogether TAMs might encourage cancer spread and lymphatic invasion in interaction 
with cancer cells 16. Furthermore, another work identified a relationship between M2 
TAMs and invasion patterns in squamous cervical cancer, noticing a significant increase 
in M2 macrophages content in tumor tissue arrays with diffuse infiltration patterns 43. 
Moreover, Petrillo et al. work showed that the differentiation of M2 macrophages 
may lead to a resistance to platinum therapies, which is in accordance with similar 
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reports for several cancer types showing evidence of a reduced effect of chemotherapy 
and radiotherapy 15,47. Dijkgraaf et. al corroborated those results showing that 
chemotherapy agents induced the proliferation of M2-like macrophages which might lead 
to an indirect therapy resistance 48 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
22 
 
Table 1 - Tumor associated macrophages and its influence in cervical lesions 
Sample Cases Antibodies Conclusion Country Reference 
Cervical specimens 130 Anti-CD68 
Anti-CD163 
Association between CD68+ and CD163+ 
macrophages and cervical carcinogenesis; 
 
Stronger correlation between CD163+ and 
advanced FIGO stage other than CD68+ 
macrophages. 
 
China 17 
Pelvic exenteration specimens from 
recurrent cervical cancer patients 
28 Anti-CD68 Higher density of TAMs within tumor cells. 
 
 
USA 49 
 
Cervical samples 90 Anti-CD68 Higher density of TAMs in CC compared to CIN I-
III and chronic cervicitis.  
China 46 
Cervix tissue from surgery patients 111 
 
Anti-CD68 and Anti-
Ki67  
Macrophage enrichment in cervical cancer nests 
and stroma when compared to the normal tissue 
and CIN III; 
 
No significant correlation between TAMs and 
FIGO stage, histological differentiation. 
 
China 16 
Cervical biopses 84 
 
Anti-CD68 Significant increase of macrophages in carcinoma 
in situ. 
 
Mexico 45 
Cervical specimens 33 Anti-CD68  Stromal macrophages are increased in HGCIN 
and CC; 
USA 50 
Uterine cervical specimens 58 Anti-CD45 
Anti-CD68 
Superior macrophage counts in CIN II, III and SCC 
compared to normal tissue; 
 
SCC with higher macrophage counts; 
 
Association between macrophage infiltration and 
progression to malignancy. 
 
Italy 51 
Cervical biopsies 112 Anti-CD68 Independent association between the increasing Brazil 52 
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Legend: 
Assays were performed by immunohistochemistry in formalin-fixed paraffin-embedded blocks of cervical tissue specimens a - Hysterectomy specimens; Ab – Antibody; CIN – 
cervical intraepithelial neoplasia; CD – Cluster of differentiation; FIGO - Fédération Internationale de Gynécologie et d'Obstétrique (staging system); HGIL – high grade 
intraepithelial lesion; LGIL – low grade intraepithelial lesion; LACC – locally advanced cervical cancer; MMP – Matrix metalloproteinase; M1/M2 – Macrophage phenotype 1 
(classically activated) or Macrophage phenotype 2 (alternatively activated); TAM – tumor associated macrophage; SCC – squamous cell cancer; 
grade of the lesion and the total macrophage 
counts;  
 
Hysterectomy specimens and cervical 
biopsies 
75 Anti-CD68 Macrophages counts did not correlate with tumor 
stage, neither survival.  
Israel 39 a 
Hysterectomy specimens and cervical 
biopsies 
50 Anti-CD68 and anti-
CD54 (ICAM-1) 
 
Invasive carcinoma with a significant increase in 
macrophages infiltrates. 
 
Israel 53 
Comercial cervical SCC tissue arrays 154 Anti-CD163 Higher mean value of M2 TAMs within intra-
tumoral samples compared to non-tumorous 
cervical SCC.  
China 43 
Blood, fresh cervical tissue and formalin-
fixed, paraffin-embedded cervical tissue 
Not 
described 
Anti-CD163 M2 increased in HGSIL and SCC compared to 
LGSIL. 
 
Increased M2 is correlated with the severity of the 
lesion. 
 
Thailand 44 
Neo-adjuvant chemoradiation 
patients 
84 Anti-CD68 
Anti-CD163 
 
M2 phenotype and low M1/M2 ratio at diagnosis is 
a marker for poor response to CT/RT; 
 
Shorter survival time in locally advanced cervical 
cancer; 
 15 
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Independently of the type of study it becomes clear that an increase in TAMs is 
an indicator of a worse prognosis 54. However, some studies have the limitation of not 
discriminating between macrophage phenotypes 46,49. In addition, M2 TAMs might also 
be causing a worse prognosis 55, revealing tumor promoting capacity demonstrated by 
Li et al., Swangphon et al. and Petrillo et al. works 15,43,44. A reduced M1/M2 ratio, as 
reported by Petrillo et. al, might explain at least to some extent, the severity 15 and is 
propitious to tumor progression 56  
To the best of our knowledge, there is no study regarding the effect of M1 
phenotype in cervical cancer. However, this phenotype was associated with a higher 
expectance of survival in non-small cell lung cancer 57, highlighting the contrasting roles 
of macrophage and need for distinguishing their phenotypes, because of their distinct 
effects. Moreover, Petrillo et. al also reported that a low M1/M2 ratio is of great 
importance for the disease outcome and implications 15. In fact, in a real molecular 
scenario, the main effect will be the result of the M1 and M2 balance, regarding the 
phenotypes contrary activities 15,27,44. 
The differences between the results of the studies, namely in the association 
between different disease stages, TAMs increase, and prognosis may reflect differences 
upon sample size, antibodies applied, tumor grade or stage included in each one, even 
though, the same methodology was applied to assess TAMs density in tumors.  
 
 TAMs influence on cervical cancer cell lines 
While the previous authors referred 17,39,43 conducted their studies with cervical 
tissue specimens, other researchers also investigated TAMs influence upon cervical 
cancer cell lines 48,51,58,59. Table 2 lists studies involving several cervical cancer cell lines 
and macrophages.  
Pedraza-Brindis and coworkers’ authors investigated whether supernatants 
produced by cervical cancer cell lines could tempt a M2 phenotype switch in THP-1 
macrophages, founding that factors secreted by cancer cells induced macrophages to 
express CD163, a characteristic M2 marker. Differences in macrophage cytokines 
produced were also observed. Cytokines associated with pro inflammatory activities 
were reduced evidencing proliferation, angiogenesis and metastasis in cervical cancer 
58. 
Sánchez-Reyes et al. evaluated the effect of cervical cancer cell lines in U937-
derived macrophages. In accordance to the previous study, macrophages under cancer 
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supernatants influence, expressed CD163 and Interleukine-10 (IL-10), presuming a 
change in immunophenotype into M2 macrophages 59. 
While investigating the impact of platinum-based chemotherapy agents on 
cervical cancer cell lines and their ability to influence the differentiation, Dijkgraaf et al. 
found that these agents promote the expression of inflammatory factors, such as IL-6 
and prostaglandin E2 (PGE2), interfering with the normal Nuclear factor-kB (NF-kB) 
signaling pathway. However, tumor cell lines induced the expansion of IL-10 producing 
M2 macrophages that reflected a decrease in immune potentiating response 48. 
Heusinkveld et al. premeditated the effect of cervical cancer supernatants on 
monocyte differentiation and fuction. Authors discovered that monocytes were skewed 
toward an M2-like phenotype, by tumor produced IL-6 and PGE2, which is in agreement 
with the previous report. However, upon interaction with T helper 1 (Th1) cells, M2 
macrophages could be switched to activated M1 macrophages with pro-inflammatory 
activity 60. 
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Table 2 - Studies on macrophages and influence of cervical cancer cell lines on macrophage differentiation and functions. 
Cell line Compounds Methodology Conclusion Studies 
HeLa 
SiHa 
C-33A 
THP-1 
Cervical cancer cell supernatants Flow cytometry Induction of M2 phenotype in THP-1 macrophages 58 
HeLa 
SiHa 
C-33A 
U937 
Cervical cancer cells 
supernatants 
Flow cytometry 
Griess assay 
HeLa, SiHa and C-33A cells induce a phenotypic change 
into M2 U937-derived macrophages. 
59 
HeLa 
CASKI 
CSCC-1 
CSCC-7 
CC-8 
Cervical cancer cells 
supernatants (after treatment 
with cisplatin and carboplatin) 
MTT assay 
Elisa 
Phosphorylated stat assay 
HeLa, CC-8 and CSCC-7 tumor supernatants skew 
macrophages into an M2-like phenotype. 
 
Chemotherapy-mediated increase of M2 macrophages may 
be an indirect mechanism for chemoresistance. 
48 
HeLa 
CASKI 
CSCC-1 
CSCC-7 
CC-8 
CC-10B 
CC-11 
Cervical cancer cells 
supernatants 
Flow Cytometry 
Elisa 
CC cell lines skew differentiation towards M2 macrophages 
by tumor-derived PGE2 and IL-6. 
60 
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These studies highlight the importance of the microenvironment in the 
carcinogenesis and development of a tumor. Tumor Infiltrating macrophages might be 
recruited and polarized by tumor secreted factors, inducing a phenotype that benefits the 
tumor survival and expansion 58, usually associated with M2 macrophages and the 
expression of CD136 as the main marker 25.  
Cytokines, as well, play a major role in tumor progression. Tumors have the ability 
to manipulate immune cells, including TAMs, which, in return, will produce specific 
cytokines that will enhance tumor growth, development, invasion and metastasis 8. 
 
Concluding remarks 
Connecting both studies, in tumor tissue and cell lines, cervical cancer, as many 
other cancers, is infiltrated by TAMs and it is mostly accepted that the severity of a lesion 
is accompanied with an increase in TAMs counts 44. This presence is frequently 
associated to a poor outcome as studies included noted 31. Moreover, cell line 
experiences corroborated the role of M2 macrophages in the suppression of the immune 
response, that allows a tumor to develop. 
Taken altogether, the tumor microenvironment, in cervical cancer, might be 
responsible for the polarization of macrophages into a M2 phenotype, characterized by 
a low antitumor activity, which facilitates the tumor development. Reason why TAMs 
density in cervical tumors is associated with a poor disease outcome and poor response 
to treatment 14,15. 
The facts presented in this paper, by the analysis of the different studies 
accessed, suggest that the increasing content of TAMs in tumor environment is related 
to the increasing grade of cervical lesions. Moreover, TAMs might express a M2 
phenotype, characterized by immune suppression, tissue remodeling and tumor 
promoting activities. The presence of this phenotype might also be a consequence of 
tumor secreted factors and an explanation to the poor outcome observed in cases of 
TAMs infiltration.  
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Main aim 
 
 
The evaluation of the biological activity of a panel of 18 chalcone derivatives on 
cervical and prostate cancer cell lines. 
 
Specific aims 
 
 
➢ Evaluation of cellular cytotoxicity of chalcone derivatives on cancer cell lines 
HeLa, LNCaP (hormone-dependent) and PC-3 (hormone-independent) cancer 
cell lines using MTT assay; 
 
➢ Evaluation of the effects of derivatives with the NO production of LPS-stimulated 
RAW 264.7 macrophages using Griess reagent; 
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Chemicals and Reagents 
 
Reagents used in cell culture, such has RPMI-1640 culture media and Fetal 
Bovine Serum was obtained from Lonza (Verviers, Belgium). Dulbecco’s Modified Eagle 
Medium/F-12 Nutrient Mixture (DMEM/F12) media was obtained from Gibco® (3 
Fountain Drive, Paisley, UK). Gentamicin solution was obtained from Sigma-Aldrich® 
(St. Louis, MO, USA). 
MTT (3-(4, 5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide) powder, was 
acquired from MERK (Darmstadt, Germany) and dissolved in phosphate buffered saline 
(PBS), from Fisher Reagent (Geel, Belgium), to a 5 mg/mL stock solution. Dimethyl 
sulfoxide (DMSO) was also purchased from MERK (Darmstadt, Germany).  
Turk solution was prepared by adding 3 mL of glacial acetic acid (CH3COOH), 
1mL of 0.5% methylene blue solution and distilled water. Methylene blue solution was 
prepared by mixing 0.5 mL of glacial acetic acid with 0.5 g of blue methylene powder and 
volume was made up to 100 mL with distilled water [131]. 
 
Chalcones 
 
 Chalcones were synthetized in the Laboratory of Organic and Pharmaceutic 
Chemistry (Faculty of Pharmacy, University of Porto) and given for testing. For 
administrative matters, related with non-published chemical structures, the compounds 
used in this work are encoded and a chemical composition cannot be revealed. 
Stock solutions were prepared by diluting compounds in DMSO, obtained from 
ACROS ORGANICS, obtaining a final 10mM concentration and stored at -20º C. Prior 
to use, compound working solutions were prepared by diluting stock solutions in 
complete medium to the final maximum concentration and 1:2 dilutions were prepared. 
 
Cell lines 
 
HeLa cell line was kindly provided by Maria José Oliveira (Institute for 
Investigation and Innovation in Health, i3S, Porto Portugal). Raw 264.7 were a gift from 
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Professor Maria S. J. Nascimento (Laboratory of Microbiology, Biological Sciences 
Department, Faculty of Pharmacy, University of Porto). 
PC-3 and LNCaP cell lines were obtained from the European Collection of Cell 
Cultures (ECCAC) and from the American Type Cell Culture (ATCC), respectively.  
HeLa, LNCaP and PC-3 cancer cell lines were cultured in 25 cm3 flasks with 
RPMI-1640 media supplied with 10% of heat-inactivated fetal bovine serum (FBS), and 
gentamicin solution at a final concentration of 1 µg/mL. 
RAW 264.7 cell lines were cultured in 75 cm3 flasks using DMEM/F12 media. 
Cells were harvested with trypsin/EDTA (HeLa, LNCaP and PC-3) and passaged, 
or scrapped (RAW 264.7) every 2-3 days.  Additionally, cell lines were maintained in an 
incubator with humidified atmosphere and 5% CO2. 
 
Cell concentration optimization assay 
 
PC3 and LnCaP cell lines were seeded (100 µL) in triplicate at increasing 
concentrations (1 x 104; 2.5 x 104; 5 x 104; 1 x 105; 2.5 x 105 and 5 x 105 cells per mL) in 
a 96 well culture plate and thereafter incubated for 24 hours to allow cell adhesion. Cell 
confluency was evaluated after 24 hours. Culture media was then removed and replaced 
with fresh culture media and incubated for 48 hours. Cell confluency was then evaluated, 
and optimal concentration was determined for cytotoxic assays. 
 
Cytotoxic assay in cancer cell lines 
 
The MTT assay is the gold standard for cytotoxicity and viability measurement 
[132]. 
 MTT is a yellow dye that is reduced by metabolically active cells into a purple 
formazan precipitate [133]. The MTT formazan precipitate is proportional to the number 
of metabolically active cells, which can then be quantified by measuring changes in 
absorbance using a plate reading spectrophotometer [134]. 
MTT reduction occurs through enzymatic conversion by dehydrogenases [135] 
not only in the mitochondria, but also in cytosol and other organelles, such as the 
endoplasmic reticulum [132, 135]. Research has found that many constituents present 
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in the cellular environment can interfere with MTT, including glycolysis inhibitors used in 
anti-cancer therapeutics [136] and even antioxidant compounds having the capability to 
interact and reduce the reagent [137]. With this, estimation of cell viability/cytotoxicity 
might reveal inconsistent [133]. 
MTT colorimetric assay was performed to measure cell viability, based on what 
is described in literature [134, 138], with a few modifications. Briefly, 1.5 x 105 cells/mL 
were seeded (100 µL) in a 96 well culture plate and incubated for 24 hours to allow cells 
to adhere. Supernatants were then removed, and test compounds were added (at 5 µM, 
10 µM and 20 µM) and incubated for 48 hours. A non-treated control was included 
without the compounds tested and supplied with culture media. Supernatants were then 
removed, cells were washed with RPMI medium and MTT solution was added at each 
well (0.5 mg/mL) and incubated for 4 hours. The MTT formazan product was solubilized 
with DMSO and absorbance (abs) was measured at 545 nm / 630 nm [139] wavelength 
using a plate reader (STAT FAX 3200). Doxorubicin was used as a positive control.
  
Percentage of cellular inhibition was calculated using the following formula [140]: 
𝐶𝑦𝑡𝑜𝑡𝑜𝑥𝑖𝑐𝑖𝑡𝑦 % =  100 −
(𝑎𝑏𝑠 𝑠𝑎𝑚𝑝𝑙𝑒)
(𝑎𝑏𝑠 𝑐𝑜𝑛𝑡𝑟𝑜𝑙)
  𝑥 100 
 
NO production assay 
 
 To determine the effect of different derivatives in NO production by RAW 264.7, 
a Griess reaction was conducted [138]. RAW 264.7 were cultured in 96 well plates at 1 
x 106 cells/mL and allowed to adhere for 2 h. Supernatants were then removed and 
replaced with 100 µL of LPS solution (1.5 µg/mL) and 100 µL of chalcone derivative (5 
µM). Cells were incubated for 24 h, at 37º C and 5% CO2 humidified atmosphere. 
100 µL of supernatants were removed and transferred to a new 96 well plate. 
Griess reagent (1% w/v sulphanilamide in 5% v/v phosphoric acid and 0.1% w/v 
naphtylethylenediamide in deionized water) was added, and plate was incubated for 10 
min at room temperature. Nitrite production was quantified by spectrophotometry at 545 
nm / 630 nm in a plate reader (STAT FAX 3200). 
From the first plate, cells were washed and MTT reagent was added. A viability 
MTT assay was conducted as previously described. 
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Inhibition of NO production and viability (MTT assay) were calculated using the 
following formulas: 
 𝐼𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 𝑜𝑓 𝑁𝑂 𝑝𝑟𝑜𝑑𝑢𝑐𝑡𝑖𝑜𝑛 % =  100 −
(𝑎𝑏𝑠 𝑠𝑎𝑚𝑝𝑙𝑒 − 𝑎𝑏𝑠 𝑏𝑙𝑎𝑛𝑘)
(𝑎𝑏𝑠 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 − 𝑎𝑏𝑠 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 )
  𝑥 100 
𝑉𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 % =  
(𝑎𝑏𝑠 𝑠𝑎𝑚𝑝𝑙𝑒 − 𝑎𝑏𝑠 𝑏𝑙𝑎𝑛𝑘)
(𝑎𝑏𝑠 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 − 𝑎𝑏𝑠 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 )
  𝑥 100 
Statistical analysis  
 
Values were selected by calculating median ± 2 x standard deviation (SD) to 
achieve meaningful results for the statistical analysis. 
Data is presented as the mean ± standard error of the mean (SEM) for the 
cytotoxicity experiment. Statistical analysis was made using Mann-Whitney analysis. A 
p value < 0.05 was considered significant. 
Analyses were done by IBM SPSS Statistics 25.0 for Windows and graphics were 
done by GraphPad Prism 7 software. 
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The anti-tumor activity of chalcone derivates was evaluated through the MTT 
cytotoxicity assay, against three cancer cell lines, namely HeLa (human cervical 
adenocarcinoma), LNCaP (human prostate carcinoma) and PC-3 (human prostate 
adenocarcinoma). The results are presented as percentage of cellular inhibition, for three 
different concentrations tested: 5 µM, 10 µM and 20 µM (Tables 3 to 5). Data was 
calculated using a formula, already cited previously. Doxorubicin (5 µM) was used as a 
reference and positive control for cellular inhibition, as it is a well-known anticancer agent 
[141, 142].  
 
Table 3 - Cytotoxicity of chalcones against HeLa cancer cell line, expressed as 
percentage of cellular inhibition (%). 
 
Compound 5 µM 10 µM 20 µM 
T 39.07 ± 0.08 33.51 ± 5.59 43.57 ± 5.73 
TB3 23.96 ± 12.47 22.44 ± 7.50 29.51 ± 4.23 
TB4 29.38 ± 10.35 20.29 ± 5.73 61.08 ± 10.08 
TH4 26.78 ± 4.97 29.32 ± 9.71 39.35 ± 13.14 
TH5 31.25 ± 4.74 33.66 ± 3.43 45.87 ± 8.56 
T4 24.97 ± 7.74 52.03 ± 7.75 74.79 ± 7.45 
T4B4 25.69 ± 3.95 45.79 ± 5.91 60.18 ± 14.53 
T4B5 11.41 ± 3.54 35.74 ± 7.11 51.64 ± 6.00 
T4H4 26.37 ± 7.07 34.35 ± 2.95 55.84 ± 7.07 
T5 14.03 ± 5.47 56.42 ± 8.59 70.20 ± 7.91 
DT 29.18 ± 8.87 31.90 ± 8.86 51.53 ± 3.29 
DF 35.80 ± 4.35 42.60 ± 8.28 85.76 ± 3.65 
PB6 46.80 ± 3.67 40.45 ± 13.53 67.95 ± 10.59 
MB 29.66 ± 11.62 63.71 ± 8.55 74.51 ± 9.05 
MB3 33.58 ± 2.41 24.52 ± 11.23 34.66 ± 8.49 
MB4 37.34 ± 12.78 57.80 ± 8.92 78.28 ± 3.03 
MB5 19.46 ± 6.83 30.25 ± 5.24 47.03 ± 8.78 
MH5 9.79 ± 3.16 21.51 ± 14.76 26.83 ± 3.85 
Doxorubicin 82.84 ± 2.47 
Note: Results are expressed as Mean ± SEM, with a minimum of 3 experiments 
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At the lowest concentration tested, 5 µM, compounds revealed low to moderate 
activity (9.79 – 46.80 %) against HeLa cell line, while compounds at 10 µM exhibited 
moderate activities (20.29 – 57.80 %). The highest concentration used, 20 µM, resulted 
in higher inhibitions and demonstrated moderate to high activity (26.83 – 85.76 %). 
Doxorubicin resulted in 82.84 % of inhibition at 5 µM, which is similar to values described 
in literature, for an exposure of 48 h [143]. 
DF registered the best activity against this cell line (85.76 % of cellular inhibition) 
for the highest concentration tested. On the contrary, MH5 had the lowest activity (26.82 
% of cellular inhibition), for the same concentration. 
 
Figure 5 depicts the most active derivatives tested against HeLa cell line. At 20 
µM derivatives showed inhibitions above 70 %. At 10 µM, rounded from 40 to 60 % of 
cellular inhibition, and at 5 µM demonstrated lower than 40 % of inhibition. 
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Figure 5 - Most cytotoxic chalcones against HeLa cell line 
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Table 4 - Cytotoxicity of chalcones against LNCaP cancer cell line, expressed as 
percentage of cellular inhibition (%). 
 
Compounds 5µM 10µM 20µM 
T 15.95 ± 5.37 33.54 ± 6.92 39.09 ± 1.10 
TB3 24.25 ± 1.87 39.17 ± 5.26 45.33 ± 4.09 
TB4 23.09 ± 8.49 40.94 ± 5.85 74.44 ± 0.80 
TH4 30.10 ± 4.88 40.47 ± 2.71 56.25 ± 2.35 
TH5 31.20 ± 2.13 49.06 ± 2.37 58.48 ± 3.73 
T4 30.39 ± 8.46 37.00 ± 8.32 63.36 ± 7.10 
T4B4 23.57 ± 0.75 34.35 ± 5.00 78.40 ± 2.57 
T4B5 24.44 ± 1.53 28.43 ± 8.17 47.83 ± 5.08 
T4H4 23.49 ± 4.83 36.93 ± 2.07 51.50 ± 7.53 
T5 29.44 ± 5.98 41.40 ± 1.38 60.02 ± 5.92 
DT 28.63 ± 4.99 31.45 ± 5.02 49.86 ± 2.09 
DF 27.36 ± 5.95 39.23 ± 4.82 69.14 ± 7.90 
PB6 37.92 ± 12.21 58.94 ± 11.22 75.07 ± 6.15 
MB 18.64 ± 2.17 43.36 ± 9.12 69.48 ± 5.30 
MB3 24.33 ± 6.41 43.95 ± 7.06 39.84 ± 10.14 
MB4 30.63 ± 4.43 52.41 ± 6.89 76.93 ± 4.56 
MB5 21.26 ± 6.69 29.34 ± 3.04 37.03 ± 3.89 
MH5 23.04 ± 9.30 33.15 ± 1.23 45.13 ± 15.32 
Doxorubicin 62.53 ± 1.82 
Note: Results are expressed as Mean ± SEM, with a minimum of 3 experiments 
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For LNCaP, at 5 µM, compounds were shown to have low to moderate inhibitory 
activity (15.95 – 37.92 %). At 10 µM, activity was moderate to relatively high (29.34 – 
58.94 %). Highest activities were achieved at the highest concentration tested, with 
values ranging from 37.03 to 78.40 %. Doxorubicin had a great activity (62.53 %), 
reducing cell viability which is  comparable with other works [143]. 
At 20 µM, T4B4, had the greatest activity against LNCaP cell line, inhibiting 78.40 
% of cells, while MB5 expressed the lowest inhibition with a value of 37.03 %.  
 
Figure 6 depicts the most active derivatives tested against LNCaP cell line. At 
the highest concentration derivatives resulted in inhibitions higher than 75 %. At 10 µM, 
PB6 and MB4 resulted in similar inhibitions, above 50 %. On the contrary, T4B4 reached 
lower values. At 5 µM, inhibition values were recorded below 40 % of cellular inhibition. 
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Figure 6 - Most cytotoxic chalcones against LNCaP cell line 
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Table 5 - Cytotoxicity of chalcones against PC-3 cancer cell line, expressed as 
percentage of cellular inhibition (%). 
 
Compounds 5µM 10µM 20µM 
T 23.5 ± 7.19 33.58 ± 10.74 47.59 ± 10.54 
TB3 31.24 ± 4.34 41.94 ± 4.02 45.40 ± 8.68 
TB4 33.40 ± 5.84 32.02 ± 5.03 84.55 ± 2.65 
TH4 33.28 ± 4.65 27.00 ± 2.75 52.25 ± 3.94 
TH5 28.36 ± 9.18 50.49 ± 3.95 63.26 ± 3.68 
T4 26.63 ± 5.42 32.17 ± 3.09 78.70 ± 2.25 
T4B4 19.63 ± 5.08 38.48 ± 5.65 62.24 ± 7.52 
T4B5 18.31 ± 0.61 33.58 ± 9.11 45.46 ± 6.29 
T4H4 31.96 ± 0.98 33.36 ± 10.69 56.25 ± 11.20 
T5 47.04 ± 5.47 33.85 ± 11.58 84.71 ± 2.86 
DT 18.44 ± 1.91 30.04 ± 2.22 60.35 ± 3.38 
DF 15.42 ± 3.76 30.01 ± 2.69 80.86 ± 5.10 
PB6 22.09 ± 6.63 44.54 ± 2.50 73.14 ± 2.77 
MB 16.13 ± 1.14 37.94 ± 11.80 57.41 ± 15.43 
MB3 17.18 ± 4.44 37.66 ± 2.41 37.00 ± 2.33 
MB4 40.83 ± 4.84 64.70 ± 1.83 87.60 ± 3.69 
MB5 19.62 ± 2.99 28.02 ± 1.44 38.88 ± 3.59 
MH5 28.69 ± 1.46 43.10 ± 2.87 59.86 ± 7.18 
Doxorubicin 73.20 ± 2.77 
Note: Results are expressed as Mean ± SEM, with a minimum of 3 experiments 
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Overall, for PC-3 cell line, low to moderate (14.93 – 47.04 %), activity was 
registered at 5 µM, while moderate to high (27.00 – 62.57 %) was recorded at 10 µM. At 
20 µM compounds exhibited moderate to high activity, with values ranging from 38.88 % 
to 87.60 % of cellular inhibition. Doxorubicin also demonstrated an accentuated toxic 
effect on cell viability, in conformity with information described [143] 
Derivatives TB4, T5 and MB4 had the highest activity with 84.55 %, 84.71 % and 
87.60 % of cellular inhibition, respectively. For this cell line, compound MB5 was the less 
active (38.88 %).  
 
Figure 7 depicts the most active derivatives tested against PC-3 cell line. At 20 
µM derivatives exceeded 80 % of inhibition. However, at 10 µM, only MB4 surpassed 60 
% of inhibition, with the other two demonstrating inhibitions rounding 30 %. At 5 µM, MB4 
and T5 achieved inhibitions higher than 40 %, while TB4 resulted in a lower inhibition 
percentage. 
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Figure 7 - Most cytotoxic chalcones against PC-3 cell line 
 
Data examination reveals that every chalcone derivative tested resulted in cellular 
inhibition against the three cancer cell lines used in this work, demonstrating cytotoxic 
and, thus, anti-tumor activity. These compounds revealed a wide range activity spectrum. 
Additionally, some derivatives do not seem to act in a dose dependent way, such as T, 
TB3 and TH4 tested in HeLa cell line; MB3 in LNCaP; TB4, TH4 and T5 in PC-3. 
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Derivative MB4 stands out for being one of the most active derivatives against 
the three cell lines. In fact, it is one of the few compounds that can achieve a cytotoxicity 
higher than 50 %, at 10 µM, and nearly 40 % of inhibition at 5 µM, while also being the 
most active at 20 µM (Figure 8). Furthermore, this derivative does not seem to show 
significant selectivity to any cancer cell line, for every concentration tested (p > 0.05). 
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Figure 8 - Cytotoxicity of MB4 derivative against cancer cell lines HeLa, LNCaP and PC-3, expressed as 
percentage of cellular inhibition (%). 
 
 
Comparing inhibitions between prostate and cervical cancer cell lines, it is 
evidenced that there are slight differences between cells. While most compounds share 
similar inhibition values between the three cell lines, few compounds were found to be 
less active against HeLa (TB3, TH4 and MH5), but demonstrating a higher activity 
against prostate cancer, at the higher concentration tested. Inhibition of HeLa cell line 
was significantly lower than LNCaP for compounds TB3 and TH4 (p < 0.05), while TH4 
and MH5 resulted in significantly lower inhibition against HeLa, when compared to PC-3 
(p < 0.05). 
On the other hand, derivatives DT and DF had a greater cytotoxicity against HeLa 
and PC-3, at 20 µM but not on LNCaP, however not significant (p > 0.05) 
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PC-3 revealed a higher sensitivity in comparison to LNCaP for some of the 
derivatives, however only three were statistically significant (p < 0.05). TB4, T5 and DT, 
at 20 µM were more active against PC-3 (Figure 9). Additionally, at 5 µM, T4B5 resulted 
in significantly higher inhibition values in LNCaP, when compared to PC-3’s (p < 0.05). 
At 10 µM, TH4 was significantly more active against LNCaP, while the opposite occurred 
for MH5, being most active in PC-3 (p < 0.05). 
 
As depicted in Figure 9, derivatives TB4, T5 and DT resulted in significant 
differences between LNCaP hormone-sensitive and PC-3 hormone-resistant cell lines. 
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Figure 9 - Cytotoxicity of chalcones against LNCaP and PC-3, expressed as percentage of cellular 
inhibition (%), at 20 µM, (p < 0.05) 
 
 
For instance, T5 resulted in 60.02 % of inhibition against LNCaP, while inhibiting 
84.71 % in PC-3. The same occurred for the derivative DT, inhibiting 49.86 % against 
LNCaP and 60.35 % of PC-3. On the contrary, T4B4 was most active against LNCaP, 
however, not considered significant (p > 0.05). 
Chalcones activity not only depends on their structure [144], but might also have 
different mechanisms of action and tumor specificity depending on the cancer disease 
[81, 91]. Chalcones can have multiple molecular targets [92, 95], and this selectivity was 
observed by several research works involving anticancer compounds and their activity 
Chalcones 
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upon different cancer cell lines [145, 146]. Heterocyclic chalcones derivatives, 
synthetized by the group of the Laboratory of Organic and Pharmaceutic Chemistry 
(Faculty of Pharmacy, University of Porto), were tested and demonstrated the anti-tumor 
activity on breast (MCF-7), lung (NCI-H460) and melanoma (A375-C5) cancer cell lines 
[147]. 
Researchers investigating anticancer hybrid chalcone based compounds found 
that, in HeLa cells, cell cycle was arrested in S and G2/M phases and induction of 
apoptosis was caspase-dependent [113]. Caspases are proteases that have a key role 
in initiating apoptosis [148]. Chalcones were also found to interfere with tubulin 
assembly, by binding to β-tubulin and elucidating the anti-mitotic and cytotoxic effect 
[149].  
For prostate cancer, a work identified an induction of G2/M cell cycle arrest while 
studying the molecular mechanism of a natural anti-cancer chalcone against PC-3 cell 
line, related with a decrease in cyclin-dependent kinase 1 (CDK1), and, moreover, 
induction of apoptosis associated with an increase in Bax pro-apoptotic protein [119]. 
Moreover, Coskun et. al demonstrated that a chalcone derivative could induce apoptosis 
by reducing mitochondrial membrane potential and caspase activity [150]. Instead, 
another study found that apoptosis in LNCaP cells treated with chalcones amplified 
TRAIL mediated apoptosis [151].  With this, demonstrating that chalcones can have 
multiple molecular targets reflecting different activities in different cancer types, as 
observed in our results. 
As for the two prostate cancer cell lines used, it becomes clear that inhibition is 
similar for most chalcone derivatives. However, there are differences between the two 
cell lines for some of the tested chalcones.  
Susceptibility differences between androgen-dependent (LNCaP) and androgen-
independent (PC-3) prostate cancer cell lines has been noted by researchers, while 
screening the anti-cancer activity of other compounds, including chalcone based ones 
[152]. One might hypothesize that there are diverse mechanisms of action underlying 
the distinct cytotoxicity results. 
LNCaP and PC-3 not only differ in androgen dependency, but also in functional 
TP53 gene expression, with LNCaP having two wild-type copies of the gene, while PC-
3 is p53-null, with a deletion in one allele and a frameshift mutation in the other [153]. 
With two copies of the gene, DNA damage response, alongside with cell cycle regulation 
and apoptosis can be triggered effectively [154]. 
A contrary variance in cytotoxic susceptibility to the ones observed in this work at 
20 µM was noted by Zhang et al., who reported greater LNCaP sensitivity to a chalcone 
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derivative and related the growth inhibition to activation of p53, at least in some extent 
[155]. 
Interestingly, Chappell et al. investigation concluded that p53 functionality is of 
great importance to the progression of prostate cancer and can dictate the sensitivity of 
the cancer and the effectiveness of a chemotherapy agent [153].  
Docetaxel is a therapeutic agent used as a first line option to treat metastatic and 
castration-resistant disease [156]. A group investigating the mechanisms that instigate 
docetaxel resistance in prostate cancer cells, found that Docetaxel treatment induced 
higher apoptosis in LNCaP when compared with PC-3 cells, corroborating the previous 
authors observations. The group also concluded that functional p53 determines 
docetaxel sensitivity in prostate cancer [157]. Higher inhibition of LNCaP cell line can be 
linked to p53 functional expression, with consequent activation when DNA is damaged 
by the effect of cytotoxic molecules, and induction of apoptosis. Contrary to our results 
at 20 µM, chalcones resulted in lower cytotoxicity against LNCaP, which might reflect 
alternative mechanism of action involved, other than p53 expression. 
 Derivative MB4 was selected to be tested on an experiment involving LPS-
stimulated RAW 264.7 murine macrophages, a cell line that is known for producing large 
quantities of NO and has been referred to as an suitable model to study inflammation 
[158, 159].   
The effect of MB4 was evaluated on NO production by Griess reaction, and 
viability was determined by MTT-assay. Preliminary results, from a single experiment, 
are presented in Table 5 and 6, respectively. 
 
Table 6 - Inhibitory effect of derivative MB4 on RAW 264.7 NO production.  
 
 
Compound Inhibition of NO 
production (%) 
MB4 10 µM 5 µM 
96.8 92.4 
Note: a total of one experiment was conducted. 
 
 
MB4 resulted in substantial inhibition of NO production, for both concentrations 
tested. At 10 µM it resulted in inhibition of 96.8 %, with identical values when tested for 
5 µM. 
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To clarify that a decrease in NO production was not related to cell death, a viability 
assay was conducted (Table 7). 
 
 
Table 7 - Effect of MB4 on RAW 264.7 viability. 
 
Compound Viability (%) 
MB4 10 µM 5 µM 
82.3 100.0 
Note: a total of one experiment was conducted. 
 
 
Firstly, for concentration 10 µM, there was 82.3 % of viable cells and at 5 µM 
there was a viability of 100 %, excluding toxicity to this cell line. 
Because it was registered nearly total viability, this NO inhibition was mostly due 
to interactions on the production itself and not due to cell death. NO inhibition 
demonstrates that this derivative has a strong anti-inflammatory activity in LPS-
stimulated RAW 264.7 macrophages, in terms of nitric oxide produced. However, these 
results are preliminary, and require further validation. 
Nitric oxide is a reactive oxygen species endogenously synthesized. Its formation 
is catalyzed by nitric oxide synthases (NOS), enzymes that convert arginine into citrulline 
leading to the production of NO during the reaction [160]. There can be multiple stimulus 
that initiate NO production, such as LPS, interleukins and cytokines [158]. 
NO is produced by three isoforms of nitric oxide synthase (NOS) [47]. Endothelial 
(eNOS/NOS3) and neuronal isoforms (nNOS/NOS1) produce relatively low quantities of 
NO, however inducible isoform (iNOS), which is expressed in macrophages, produces 
much larger amounts of product [161, 162]. 
While NO has an important role as mediator of inflammation, acting as a pro-
inflammatory molecule, for example, in a bacterial infection [47], it can have contradictory 
effects when overproduced, leading to tissue destruction [47], DNA damage [163], 
inhibition of apoptosis [164] and to either promote or inhibit tumor progression [161].  
iNOS expression and activation is regulated by several cytokines and microbial 
products, with many transcriptional factors and signaling pathways involved [47]. It is 
regulated at various levels, such as transcription, post-transcription, translation and pros-
translational level [165, 166]. Another possibility for the reduction in NO produced, can 
be the result of the free radical-scavenging effect, partially attributed to chalcones [167]. 
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Without further investigation, the derivative tested can act as a direct or indirect 
inhibitor of iNOS, a key enzyme in NO production, or even reduce NO production by 
chalcone scavenging effect. Subsequent experiments are needed to confirm these 
results and to clarify the exact mechanism of NO production inhibition, as well as the 
influence on cytokines produced and gene expression of involved enzymes, behind 
these observations.  
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Conclusion 
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 In this work, a panel of 18 chalcone derivatives were tested for their antitumor 
activity on three cancer cell lines. 
Every chalcone exhibited promising antitumor activity on cervical HeLa and 
prostate LNCaP and PC-3 cancer cell lines. Most importantly, there were differences 
between the cell lines, in specific, between hormone dependent and independent 
prostate cell lines. In fact, for three of the chalcone compounds, a significantly higher 
sensitivity of PC-3 was observed, in comparison to LNCaP. These results might point to 
specific cellular sensibility and different mechanisms of action, particularly concerning 
the prostate castration resistance. 
 Compound MB4 was highlighted for its great inhibitory activity on the three cell 
lines. Even at lower concentrations it resulted in a high percentage of cellular inhibition, 
against the three lines. 
It was thus interesting to investigate the function of this molecule and role in the 
immune system. While MB4 does not seem to affect RAW 264.7 macrophages viability, 
it appears to expressively decrease the nitric oxide production, leading to the hypothesis 
that this chalcone might also share anti-inflammatory activity, at least in terms of NO 
produced. 
Further studies are required to confirm the result and to clarify the role of 
chalcones on the immune system. 
 
 
Future Perspectives 
 
As future perspectives it would be interesting to: 
➢ Study the effect of chalcones on NO production by macrophages, and determine 
the mechanism involved.  
 
➢ Study the effect of the chalcone derivatives on the interaction between human 
macrophages and cancer cell lines. 
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